tbuckley/cabot-search huggingface dataset:
In Reply:
Authors: Lance C. Pagliaro
Journal: Journal of Clinical Oncology (2004)

tion of a single major genetic alteration, such as a p53 mutation, could circumvent the redundant survival pathways activated in cancer.Suicide or immunomodulatory transgenes, for example, seem to be exceedingly more attractive payload approaches.It also would have been interesting to investigate the levels of antibodies against Ads, of CAR receptors in tumor samples, and the mutational status of p53 in every patient.Immunohistochemical overexpression of p53 confers a worse prognosis in bladder cancer but does not necessarily correlate with a nonfunctional protein.Finally, although chemotherapy and radiotherapy were not administered by Pagliaro et al, we would like to emphasize that these natural partners in therapeutic combos have to be carefully integrated.A suitable time schedule and the selection of proper drugs are elements that have been largely forgotten in other studies.Gene therapy had a rocky start in the new millennium.The early 1990s were thought to be the best of times for gene therapy.But early hopes were frustrated by the many steps necessary to produce success, as with major achievements in every field, such as space exploration, with the first moon landing.In this way, we have learned many lessons and also can guess new routes.
Les troubles de I'élimination urinaire de l'eau: Étude physio-pathologique et clinique
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Outcomes after HLA-Matched Sibling Transplants or Chemotherapy in Children with Acute Lymphoblastic Leukemia in Second Remission: A Collaborative Study of the Children’s Oncology Group (COG) and the Center for International Blood and Marrow Transplant Research (CIBMTR).
Authors: Mary Eapen, Elizabeth Raetz, Mei-Jie Zhang, Catherine Muehlenbein, Meenakshi Devidas, Thomas Abshire, Amy Billett, Alan Homans, Bruce Camitta, William Carroll, Stella Davies
Journal: Blood (2005)
MD Lists Five Points to Improve Overseas Health
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Seal finger
Authors: Matthew R Lewin, Peter Knott, Marvin Lo
Journal: The Lancet (2004)

A 33-year-old female biologist presented with an exquisitely tender, swollen, right index finger (figure), with a violaceous blister on its dorsum, 5 days after getting a small cut while radiotagging the flippers of elephant seals (Mirounga lionina) off the coast of San Francisco, California. We considered erysipeloid, Vibrio vulnificus infection, and seal finger (also known as "spekk" or "blubber" finger) as possible diagnoses. Outside Scandinavia, Greenland, and the Canadian Arctic, seal finger is regarded as unusual. It is probably caused by marine mycoplasma found in mouths and bodily waste of Pinnipedia. Traditionally an occupational hazard of seal hunters, it is increasingly common in wildlife workers. Symptoms may appear 1 day to 3 weeks after exposure. Since mycoplasma lack a cell wall, the disease does not respond to beta-lactam antibiotics. Prompt recognition and treatment with the correct antibiotics are essential to prevent permanent disability. The patient's symptoms resolved with a 4-week course of tetracycline. Department of ErrorLewin MR, Knott P, Lo M. Seal finger. Lancet 2004; 364: 448—In this Clinical Picture (July 31), the elephant seal should be identified as Mirounga angustirostris. Full-Text PDF
Memoirs of a Surgical House Office 1936-1942, Vanderbilt University Hospital
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Risk factors for male to female transmission of HIV. European Study Group.
Journal: BMJ (1989)

OBJECTIVE--To identify risk factors for sexual transmission of HIV from infected men to their female sexual partners. DESIGN--Cross sectional analysis as part of a continuing study. Data were obtained by interviewing heterosexual couples in which the man was infected with HIV. Risks were assessed by comparing couples in which transmission had occurred (woman infected with HIV) with those in which it had not (woman not infected) and estimated by independent odds ratios and their 95% confidence intervals. SETTING--Infectious disease and public health departments from nine centres in six European countries. PARTICIPANTS--153 Male index patients (mean age 30.4 years) and their 155 female partners (mean age 27.8 years). INTERVENTIONS--Women were tested to determine their HIV antibody state. Women with a risk of infection with HIV other than sexual contact with their infected partner were excluded. END POINT--Three risk factors for male to female transmission of HIV. MEASUREMENTS AND MAIN RESULTS--Three risk factors were identified: a history of sexually transmitted disease in the previous five years for the female partner (odds ratio 3.1, 95% confidence interval 1.1 to 8.6); index patient with full blown AIDS (5.4, 1.2 to 25.2); and practice of anal intercourse (5.8, 2.3 to 14.8). The proportion of women positive for HIV antibody was 27% (42/155), ranging from 7% (1 to 13%) (4/60) for couples with none of the three risk factors to 67% (45 to 89%) (12/18) for those with two or three of the risk factors. Duration of the relationship (median three years), frequency of sexual contacts, sexual practices other than anal intercourse, and contraceptive behaviour were not associated with infection of the partner. CONCLUSIONS--The risk of sexual transmission of HIV from an infected man to his female partner varies considerably according to the characteristics of the couple. The differences in rates of transmission in high risk groups may be considerably reduced if the risk factors are taken into account during individual and public health counselling.
Book Review Congenital Club-Foot (Talipes Equinovarus) . With 92 illustrations. By E. P. Brockman, M.Ch., F.R. C.S., Orthopaedic Surgeon, Westminster Hospital; Assistant Surgeon, The Royal National Orthopaedic Hospital; Surgeon to St. Vincent's Orthopaedic Hospital. Bristol: John Wright &amp; Sons Ltd., London: Simpkin Marshall Ltd., 1930.
Journal: New England Journal of Medicine (1930)
PRELIMINARY ARRANGEMENTS.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Baseline demographics of patients from the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET).
Authors: Simron Singh, Roberto Buzzoni, Carlo Carnaghi, Nicola Fazio, Marianne E. Pavel, Edward M. Wolin, Jiri Tomasek, Markus Raderer, Harald Lahner, Du Hung Lam, Helene Cauwel, Juan W. Valle, Gianfranco Delle Fave, Eric Van Cutsem, Jonathan R. Strosberg, Margot Et Tesselaar, Yasuhiro Shimada, Do-Youn Oh, Matthew H. Kulke, James C. Yao
Journal: Journal of Clinical Oncology (2015)

e15197 Background: NET are malignant tumors arising from neuroendocrine cells throughout the body. Everolimus (EVE), a mammalian target of rapamycin inhibitor, is approved for the treatment of advanced, well-differentiated pancreatic NET. There is an unmet medical need in Gl and lung NET; targeted therapies, such as everolimus, are of particular interest. Methods: Patients with advanced nonfunctional NET of Gl or lung origin with progressive disease (PD) within the past 6 months were randomized (2:1) to EVE 10 mg/d or placebo, both with best supportive care. Concomitant use of somatostatin analogue (SSA) was not allowed during the study, except for control of emergent carcinoid symptoms not manageable by standard therapy. Patients were stratified based on tumor sites, prior SSA exposure, and WHO performance status (PS) at baseline. Primary end point was progression-free survival (PFS) as assessed by central radiology review using modified RECIST 1.0 criteria. Primary analysis is planned after 176 PFS events. Crossover to open label EVE after progression would not be allowed prior to the primary analysis. Overall survival was the key secondary end point. Results: Recruitment has been completed. Of 388 patients screened, 302 were randomized. Median age was 63 years, 53% were females, and majority of them (76.2%) were Caucasians. The most common tumor sites were lung (29.8%), ileum (23.5%), and rectum (13.2%). WHO PS was zero in 219 (72.5%) patients and 1 in 82 (27.2%) patients; 52% had received SSA prior to study entry. As of September 16, 2013, 173 (57.3%) patients remained on treatment, 127 (42.1%) discontinued treatment and 2 (0.7%) were not treated. PD (24.2%) and adverse events (10.6%) were the most common reasons for treatment discontinuation. Results of primary analysis are expected by early 2015. Conclusions: RADIANT-4 is the first phase Ill study to assess efficacy and safety of EVE in patients with nonfunctional NET of Gl or lung origin. Noncrossover design and prospective stratification of the population based on known prognostic factors should minimize confounding in the estimation of the treatment effect. Clinical trial information: NCT01524783.
THE COAGULATION BALANCE AND THROMBOLYSIS
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Factors Associated with Serum Levels of Estradiol and Sex Hormone-Binding Globulin among Premenopausal Japanese Women
Authors: Chisato Nagata, Nobuyuki Kaneda, Michinori Kabuto, Hiroyuki Shimizu
Journal: Environmental Health Perspectives (1997)

We measured serum levels of estradiol (E(2)) and sex hormone-binding globulin (SHBG) among 50 healthy premenopausal Japanese women in 1994 in Gifu, Japan, to investigate the relationships between potential risk factors for breast cancer and hormone levels. Using a self-administered questionnaire, we collected data on body size, physical activity, and previous disease history, as well as menstrual and reproductive histories of the woman and her mother. Blood samples were drawn from each subject on the 11th and 22nd days of her menstrual cycle. Higher serum E(2) levels were observed for women with shorter menstrual cycles. Age as well as cycle length were included in the regression models to determine the associations between hormone levels and study variables. Body mass index (BMI) was inversely related to SHBG level measured at the 11th day of the cycle, after adjusting for age and cycle length (r = -0.33; p = 0. 03). Women born in spring/summer had higher levels of E(2) on the 22nd day (p = 0.07) and higher levels of SHBG on both the 11th and 22nd days of the cycle (p = 0.01 and p = 0.06, respectively) than those born in other seasons. Physical activity at 13-15 years of age was inversely related to E(2) level on the 11th day of the cycle after controlling for age, cycle length, BMI, and birth month (r = -0.35; p = 0.04).
Prevalence of Headache among Handheld Cellular Telephone Users in Singapore: A Community Study
Authors: Sin-Eng Chia, Hwee-Pin Chia, Jit-Seng Tan
Journal: Environmental Health Perspectives (2000)

We carried out a cross-sectional community study in Singapore to determine the prevalence of specific central nervous system (CNS) symptoms among hand-held cellular telephone (HP) users compared to nonusers and to study the association of risk factors and CNS symptoms among HP users. A total of 808 men and women between 12 and 70 years of age, who lived in one community, were selected using one-stage cluster random sampling and responses to a structured questionnaire. The prevalence of HP users was 44.8%. Headache was the most prevalent symptom among HP users compared to non-HP users, with an adjusted prevalence rate ratio of 1.31 [95% confidence interval, 1.00-1.70]. There is a significant increase in the prevalence of headache with increasing duration of usage (in minutes per day). Prevalence of headache was reduced by more than 20% among those who used hand-free equipment for their cellular telephones as compared to those who never use the equipment. The use of HPs is not associated with a significant increase of CNS symptoms other than headache.
FRACTURE FRAME
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Control of albumin gene expression during liver regeneration . Medical Hochschule Hannnover, FRG and University of Modena*, Italy
Journal: Hepatology (1995)

In this study, we used [3H]thymidine labeling of newly synthesized DNA to examine the earliest effects of 2-acetylaminofluorene (2-AAF) on the mitotic activation of cells in the adult rat liver, and in situ hybridization analysis to study the expression of three transcription factors (HNF1 beta, HNF3 gamma, and HNF4), and two of the genes (alpha-fetoprotein [AFP] and albumin) regulated by these factors. A low dose of 2-AAF (and its analogs, 2-AF [2-aminofluorene] and N-OH-2-AAF) elicited a mitogenic response in ductal cells and nondescript periductular cells within 24 hours after administration. The compounds also induced the expression of HNF1 beta, HNF3 gamma, AFP, and albumin in ductal structures but had no detectable effect of HNF4 expression. In contrast, initiation of bile duct proliferation by ligation of the common bile duct had no effect on the expression of these genes in ductal cells. In addition to inducing a mitogenic response, 2-AAF resulted in increased numbers of apoptotic cells in the portal areas, a process that contributed to overall retention of liver morphology. Our results demonstrate that 2-AAF and some of its analogs can elicit a specific mitogenic response and induce expression of the "establishment" transcription factors, HNF1 beta and HNF3 gamma, in ductal cells. Our data provide further support of a precursor-product relationship between "stem-like" cells located in ductal structures, oval cells, and hepatocytes. (Hepatology 1996 Jan;23(1):62-70)
DERMATITIS VEGETANS
Authors: W. ALLAN JAMIESON
Journal: British Journal of Dermatology (1902)

THE term vegetative is one employed in dermatology to denote a type of exuberant, cutaneous, epithelial over-growth, in its general features resembling roughly the aspect of a thin slice cut from a head of cauliflower.This is not necessarily the appanage of any particular skin-disease, but is encountered under many and varying conditions.Perhaps the most familiar of these is the well-known condyloma or mucous patch, so frequently met with about the genital organs or in situations where two surfaces come much or constantly in contact in the course of early syphilis.As an occasional phenomenon in connection with ringworm we find this vegetative process in kerion, in some examples of tines barbm, and in conglomerate pustular folliculitis, now assigned to the results of the germination of the trichophyton in the Bkin.It is also the distinctive character in pemphigus vegetans, it is seen in Darier's disease, something very like it is to be recognised in Paget's disease of the nipple-mamillitis maligna-and the patches of blastomycetic dermatitis exhibit peculiarities allied to it.One character common to all-Paget'e disease excepted-is that the symptom does not possess the property of permanence.After lasting a more or less definite period the growths wither and are absorbed, either leaving no trace, a reddish macule, or some VOL.XIV.
THE DEATH OF MR. ERNEST HART.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal